A 42-year-old woman with cystic fibrosis is admitted with acute exacerbation of Pseudomonas aeruginosa lung infection. She is prescribed tobramycin 7 mg/kg IV once daily for 14 days. Her baseline renal function is normal (serum creatinine 0.8 mg/dL, eGFR 95 mL/min/1.73m²). On day 10, she develops vertigo, nausea, and nystagmus. Audiometry shows high-frequency sensorineural hearing loss. Which of the following best describes the pharmacokinetic property of aminoglycosides that predisposes to this adverse effect, and what is the most appropriate management?

Explanation

## Pharmacokinetic Basis of Aminoglycoside Ototoxicity **Key Point:** Aminoglycosides are **concentration-dependent killers**, but this property does NOT protect against ototoxicity. Once-daily dosing was designed to minimize nephrotoxicity (by reducing cumulative renal exposure), not ototoxicity. **High-Yield:** Ototoxicity is driven by **total cumulative dose** and **inner ear accumulation**, not by peak concentration. Aminoglycosides enter the inner ear via the perilymph and accumulate irreversibly in endolymph, where they destroy cochlear and vestibular hair cells. ## Mechanism of Inner Ear Accumulation ```mermaid flowchart TD A[Aminoglycoside IV dose]:::action --> B[Systemic circulation]:::outcome B --> C[Enters perilymph via round window]:::action C --> D[Accumulates in endolymph]:::outcome D --> E[Binds to hair cell membranes]:::action E --> F[Generates ROS, mitochondrial damage]:::action F --> G[Irreversible hair cell death]:::urgent G --> H[Permanent hearing loss + vestibular dysfunction]:::urgent ``` ## Why Ototoxicity is Irreversible | Aspect | Details | |--------|----------| | **Hair cell turnover** | Inner ear hair cells do not regenerate in humans (unlike birds/reptiles) | | **Mechanism** | Aminoglycosides inhibit mitochondrial protein synthesis → ATP depletion → apoptosis | | **Timing** | Can occur during therapy or even after discontinuation (delayed ototoxicity) | | **Reversibility** | Once hair cells die, hearing loss is permanent | **Clinical Pearl:** The presence of vertigo + nystagmus + high-frequency SNHL indicates vestibular and cochlear involvement. This is a medical emergency requiring immediate drug discontinuation. ## Why Once-Daily Dosing Does NOT Prevent Ototoxicity **Warning:** A common misconception is that once-daily aminoglycoside dosing (which reduces nephrotoxicity) also reduces ototoxicity. **This is false.** Ototoxicity depends on cumulative dose and inner ear concentration, not dosing interval. ## Management 1. **Discontinue tobramycin immediately** — further exposure will worsen hearing loss and vestibular dysfunction 2. **Switch to an alternative antipseudomonal agent**: - Fluoroquinolone (e.g., levofloxacin, ciprofloxacin) - Beta-lactam + beta-lactamase inhibitor (e.g., piperacillin-tazobactam) - Azithromycin (if susceptible) 3. **Document hearing loss** — baseline audiometry for medicolegal purposes and monitoring of progression 4. **Vestibular rehabilitation** — may help with symptom management but does not restore function **Mnemonic:** **STOP AG** = **S**ensory loss (hearing/vestibular), **T**oxicity is irreversible, **O**ther agents available, **P**ermanent damage, **A**minoglycosides must be discontinued, **G**et alternative.